Actively Recruiting
Cancer and Immune Cell Metabolism in Patients With Hematological Malignancies
Led by University Hospital, Basel, Switzerland · Updated on 2025-12-23
350
Participants Needed
1
Research Sites
787 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study investigates how metabolism in cancer and immune cells shapes the bone marrow environment, influences therapy resistance, and affects outcomes in hematological malignancies.
CONDITIONS
Official Title
Cancer and Immune Cell Metabolism in Patients With Hematological Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years
- Signed written informed consent
- Diagnosis of MDS, AML, ALL, PMF, or post-ET/PV MF for participants with hematological cancers
You will not qualify if you...
- Pregnant or lactating women
- Inability to give consent
- Active malignant disease other than MDS, AML, ALL, PMF, or post-ET/PV MF within the last 3 years
- For healthy donors: previous or current hematological disease or other malignant disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Basel
Basel, Switzerland, 4031
Actively Recruiting
Research Team
P
Petya Apostolova, Prof. Dr.
CONTACT
J
Johannes Tossounidis, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here